Catabasis Pharmaceuticals (CATB) Shares are Up 41.28%

Catabasis Pharmaceuticals (CATB) : Traders are bullish on Catabasis Pharmaceuticals (CATB) as it has outperformed the S&P 500 by a wide margin of 28.49% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 41.05%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 41.28% in the last 1 week, and is up 27.8% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

The stock has recorded a 20-day Moving Average of 38.25% and the 50-Day Moving Average is 35.27%.The 200 Day SMA reached 16.8%


Catabasis Pharmaceuticals (NASDAQ:CATB): The stock opened in the green at $6.5 on Friday, but the bulls found it difficult to push the prices higher. The stock reached a high of $6.63 and a low of $5.75 for the day. The stock did not find buyers even at the lows and closed at $6.16 recording a loss of -1.44%. 1,972,345 shares exchanged hands during the trading day. The stock had closed at $6.16 in the previous days trading.

Catabasis Pharmaceuticals (CATB) : The consensus price target for Catabasis Pharmaceuticals (CATB) is $23.33 for the short term with a standard deviation of $6.51. The most optimist securities analyst among the 3 who monitor the stock believes that the stock can reach $30, however, the pessimist price target for the company is $17.

Catabasis Pharmaceuticals, Inc. (Catabasis) is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapeutics based on its safely metabolized and rationally targeted (SMART) linker technology platform. Its SMART linker technology platform is based on the concept of treating diseases by simultaneously modulating various biological targets in one or more related disease pathways. Catabasis engineers bi-functional product candidates that are conjugates of two molecules, or bioactives, each with known pharmacological activity, joined by one of its SMART linkers. Catabasis is also engaged in developing other product candidates for the treatment of lipid disorders. The Companys product development pipeline includes three clinical-stage product candidates, namely, CAT-1004, CAT-2000 series, including CAT-2054 and CAT-2003, and CAT-4001, and various programs in preclinical development.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *